JP2020502248A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502248A5 JP2020502248A5 JP2019534685A JP2019534685A JP2020502248A5 JP 2020502248 A5 JP2020502248 A5 JP 2020502248A5 JP 2019534685 A JP2019534685 A JP 2019534685A JP 2019534685 A JP2019534685 A JP 2019534685A JP 2020502248 A5 JP2020502248 A5 JP 2020502248A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- preparation according
- treating
- compound
- cerebral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 3
- 208000031464 Cavernous Central Nervous System Hemangioma Diseases 0.000 claims 2
- 201000008450 Intracranial aneurysm Diseases 0.000 claims 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 206010047163 Vasospasm Diseases 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022105969A JP7461414B2 (ja) | 2016-12-21 | 2022-06-30 | Ｒｈｏキナーゼ阻害剤ＢＡ‐１０４９（Ｒ）及びその活性代謝物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437181P | 2016-12-21 | 2016-12-21 | |
| US62/437,181 | 2016-12-21 | ||
| PCT/US2017/031836 WO2018118109A1 (en) | 2016-12-21 | 2017-05-09 | Rho kinase inhibitor ba-1049 (r) and active metabolites thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022105969A Division JP7461414B2 (ja) | 2016-12-21 | 2022-06-30 | Ｒｈｏキナーゼ阻害剤ＢＡ‐１０４９（Ｒ）及びその活性代謝物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502248A JP2020502248A (ja) | 2020-01-23 |
| JP2020502248A5 true JP2020502248A5 (enExample) | 2020-06-18 |
| JP7117306B2 JP7117306B2 (ja) | 2022-08-12 |
Family
ID=62627011
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019534685A Active JP7117306B2 (ja) | 2016-12-21 | 2017-05-09 | Ｒｈｏキナーゼ阻害剤ＢＡ‐１０４９（Ｒ）及びその活性代謝物 |
| JP2022105969A Active JP7461414B2 (ja) | 2016-12-21 | 2022-06-30 | Ｒｈｏキナーゼ阻害剤ＢＡ‐１０４９（Ｒ）及びその活性代謝物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022105969A Active JP7461414B2 (ja) | 2016-12-21 | 2022-06-30 | Ｒｈｏキナーゼ阻害剤ＢＡ‐１０４９（Ｒ）及びその活性代謝物 |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP3558314B1 (enExample) |
| JP (2) | JP7117306B2 (enExample) |
| DK (1) | DK3558314T3 (enExample) |
| ES (1) | ES3002432T3 (enExample) |
| FI (1) | FI3558314T3 (enExample) |
| PL (1) | PL3558314T3 (enExample) |
| PT (1) | PT3558314T (enExample) |
| WO (1) | WO2018118109A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10857157B2 (en) | 2015-01-26 | 2020-12-08 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
| US10106525B2 (en) | 2015-01-26 | 2018-10-23 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
| EP3558314B1 (en) * | 2016-12-21 | 2024-10-23 | Bioaxone Biosciences, Inc. | Rho kinase inhibitor ba-1049 (r) and active metabolites thereof |
| US11198680B2 (en) | 2016-12-21 | 2021-12-14 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
| US10537567B2 (en) | 2017-07-11 | 2020-01-21 | BioAxone BioSciences, Inc. | Kinase inhibitors for treatment of disease |
| DK3877364T3 (da) * | 2018-11-06 | 2024-09-23 | Cervello Therapeutics LLC | Rock-kinasehæmmere |
| JP7015360B2 (ja) | 2019-11-01 | 2022-02-02 | キリンホールディングス株式会社 | 多成分試料における物質の構造決定方法 |
| WO2021100852A1 (ja) * | 2019-11-21 | 2021-05-27 | キリンホールディングス株式会社 | 結晶スポンジ法による構造解析のための結晶構造解析用試料の調製方法 |
| JP7213839B2 (ja) * | 2019-11-21 | 2023-01-27 | キリンホールディングス株式会社 | 結晶スポンジ法による構造解析のための結晶構造解析用試料の調製方法 |
| CN115975940B (zh) * | 2021-10-15 | 2025-09-02 | 合肥中科普瑞昇生物医药科技有限公司 | 胃癌原代细胞的培养基和培养方法 |
| CA3238227A1 (en) | 2021-11-11 | 2023-05-19 | The Doshisha | Cryopreservation preparation for corneal endothelial cells and method for producing said cryopreservation preparation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004106325A1 (en) * | 2003-05-29 | 2004-12-09 | Schering Aktiengesellschaft | Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl)homopiperazine |
| WO2005080394A1 (en) | 2004-02-24 | 2005-09-01 | Bioaxone Therapeutique Inc. | 4-substituted piperidine derivatives |
| JP4652112B2 (ja) | 2005-04-26 | 2011-03-16 | 富士フイルム株式会社 | 投射型表示装置 |
| CA2679263A1 (en) | 2007-02-28 | 2008-09-04 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
| MX2011001370A (es) | 2008-08-05 | 2011-03-15 | Abbott Lab | Compuestos utiles como inhibidores de cinasas de proteina. |
| WO2012170554A1 (en) | 2011-06-06 | 2012-12-13 | Theodore Mark Kamenecka | N-biphenylmethylindole modulators of pparg |
| EP3489239B1 (en) * | 2013-03-06 | 2021-09-15 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
| JP6581111B2 (ja) * | 2014-04-28 | 2019-09-25 | メッドシャイン ディスカバリー インコーポレイテッド | Ｒｈｏキナーゼ阻害剤としてのイソキノリンスルホン誘導体 |
| US9902702B2 (en) * | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
| US9687483B2 (en) * | 2015-01-26 | 2017-06-27 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with Rho kinase inhibitors |
| EP3558314B1 (en) | 2016-12-21 | 2024-10-23 | Bioaxone Biosciences, Inc. | Rho kinase inhibitor ba-1049 (r) and active metabolites thereof |
-
2017
- 2017-05-09 EP EP17882341.5A patent/EP3558314B1/en active Active
- 2017-05-09 JP JP2019534685A patent/JP7117306B2/ja active Active
- 2017-05-09 WO PCT/US2017/031836 patent/WO2018118109A1/en not_active Ceased
- 2017-05-09 EP EP24208222.0A patent/EP4509138A3/en active Pending
- 2017-05-09 PT PT178823415T patent/PT3558314T/pt unknown
- 2017-05-09 PL PL17882341.5T patent/PL3558314T3/pl unknown
- 2017-05-09 ES ES17882341T patent/ES3002432T3/es active Active
- 2017-05-09 DK DK17882341.5T patent/DK3558314T3/da active
- 2017-05-09 FI FIEP17882341.5T patent/FI3558314T3/fi active
-
2022
- 2022-06-30 JP JP2022105969A patent/JP7461414B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514910A5 (enExample) | ||
| FI3558314T3 (fi) | Rho-kinaasin estäjä ba-1049 (r) ja sen aktiivisia aineenvaihduntatuotteita | |
| JP2022540935A5 (enExample) | ||
| MA49402A (fr) | Polynucléotides aadc pour le traitement de la maladie de parkinson | |
| JP2014221779A5 (enExample) | ||
| EP3471660A4 (en) | MEDICAL DEVICE FOR THE TREATMENT OF VASCULATORS | |
| JP2017506627A5 (enExample) | ||
| JP2015513557A5 (enExample) | ||
| EP4241772A3 (en) | Process for the preparation of compounds useful for treating spinal muscular atrophy | |
| WO2015171610A3 (en) | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease | |
| WO2017090039A3 (en) | Pharmaceutical compositions comprising levodopa amide and uses thereof | |
| EP3412668A3 (en) | A selective inhibitor of phosphatidylinositol 3-kinase-gamma | |
| MA55917A (fr) | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie | |
| JP2017517565A5 (enExample) | ||
| MX2020012336A (es) | Formulacion farmaceutica. | |
| EP3419981A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY | |
| WO2017117070A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| WO2018071741A8 (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
| JP2016540015A5 (enExample) | ||
| WO2015001541A3 (en) | Pharmaceutical film composition | |
| PH12015501793A1 (en) | Bicyclic compounds | |
| MX2017005586A (es) | Piperidinilpirazolopirimidinonas y utilización de las mismas. | |
| WO2017105881A8 (en) | Deuterated compounds for treating pain | |
| LT3124048T (lt) | Kompozicija skirta vartoti per burną gastroezofaginio refliukso ligos ar skausmo gydymui | |
| FR3067611B1 (fr) | Procede pour le traitement d'un tissu cerebral |